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Abstract
Introduction This study examined potential biomarkers for
the diagnosis and early detection of chronic allograft
rejection after lung transplantation.
Methods Protein ratios in pooled samples of bronchoalveo-
lar lavage fluid (BALF) from lung transplant recipients at
different stages of pre- and postchronic rejection were
determined by iTRAQ labeling and mass spectrometry. The
potential biomarkers were validated using enzyme-linked
immunosorbent assay (ELISA) assay.
Results Two hundred sixty-five proteins were identified,
about two thirds of which showed more than a twofold
difference between a pooled control sample (individuals
who did not develop chronic rejection in 100 months) and a
pooled sample from those with chronic rejection. Proteinase
3 (PR-3) and matrix metalloproteinase 9 (MMP-9) were
validated by ELISA assay of 124 individual samples. PR-3
and the latent form of MMP-9 (proMMP9) both demon-
strated a specificity of 92% with sensitivities of 76% and
82%, respectively, for disease diagnosis; both were also
predictors of developing chronic rejection up to 15 months
before diagnosis. While immunoglobulin M (IgM) was
upregulated in the pooled samples, individual sample
analysis revealed that this arose from outlier values.
Conclusions iTRAQ can be used to detect a large number of
proteins in pooled samples for the discovery of potential
biomarkers, but the findings must be validated with technology
capable of distinguishing broadly based changes from out-
comes as a result of a few extreme cases. The proteins identified
in this study expanded the panel of potential biomarkers for the
diagnosis and prediction of chronic rejection and provided
additional insight into the mechanism of the disease.
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Introduction
Chronic lung allograft rejection, characterized by inflam-
mation, fibrosis, and proliferation of the small airways, has
remained a major obstacle for the long-term survival after
lung transplantation [1, 2]. The five-year survival rate of
lung transplant recipients is less than 50%, of which about
30% is attributed to chronic rejection [1]. Furthermore,
about 50–60% of patients who survive for 5 years beyond
lung transplantation are affected by chronic rejection [3].
Chronic rejection is histologically manifested by oblitera-
tive bronchiolitis (OB) or clinically as bronchiolitis oblit-
erans syndrome (BOS). At present, BOS is diagnosed by
standard lung function tests [4, 5], either the progressive
decline in forced expiratory volume in 1 s (FEV1) and/or
by mid-expiratory flow rates (FEF25–75). Unfortunately, the
clinical symptoms of airway obstruction caused by fibro-
proliferation are irreversible, making discovery of bio-
markers for early detection an important goal.
Systematic searches for inflammation and fibrosis
mediators in the airways have been reported in lung
allograft rejection. Elevated levels of several chemokines
from epithelial cells, proteases from neutrophils, and
profibrotic cytokines have been associated with BOS [6–
11]. Such targeted studies focus on the effect of one protein
or protein family. However, the pathogenesis of BOS
involves many complex processes, such as host immunity,
alloimmune response, lymphocyte activation, and viral and/
or bacterial infections [3, 12, 13]. An understanding of
cellular mechanisms of chronic rejection requires a thor-
ough knowledge of proteins expressed during the process.
Broad-based, non-biased searches for protein biomarkers of
BOS can expand the base of potential biomarkers and
improve our understanding of this disease.
Previous studies used bronchoalveolar lavage fluid
(BALF), a widely available source of proteins for studying
lung-related diseases [14], and matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry demonstrated human neutrophil defensins,
Clara cell protein, lysozyme, and a number of other BALF
components as biomarkers for the early detection of chronic
lung transplant rejection [15–17]. The results also provided
the hypothesis that a major contributor to loss of lung
function in BOS was over-activation of the innate immune
system. While sensitivity and specificity were excellent, it
was clear that additional biomarkers were needed to attain
the desired ability to predict BOS well before the onset of
clinical symptoms.
Another attractive approach for the comparison of
proteins in a complex mixture is iTRAQ technology, a
method that uses isobaric tags to label and simultaneously
compare up to four samples. Peptides of four different
samples are labeled separately with a different reporter
group and then mixed before analysis by mass spectrom-
etry. The relative amount of each peptide from the four
samples is estimated from the relative intensity of the
specific tag applied to each sample. A challenge for
virtually all methods that detect proteins by peptide analysis
is incomplete coverage of peptides in the mixture. This
results in a different set of peptides and proteins identified,
even in consecutive runs on the same sample. That is, a
second iTRAQ run will yield only partial overlap of
peptides identified in the first run. Comparison of the same
protein in all samples requires orthogonal methods to
validate the iTRAQ findings, such as a quantitative
enzyme-linked immunosorbent assay (ELISA) assay.
This study used iTRAQ technology for discovery of
additional biomarkers for chronic lung transplant rejection.
Biomarkers were then validated by ELISA assay of each
sample. Outcomes provided proteinase 3 and MMP-9 as
additional biomarkers of BOS. These will contribute to the
ultimate development of a panel of biomarkers needed for
the accurate prediction of future disease.
Materials and Methods
Chemicals and Reagents The iTRAQ™ reagent kit was
purchased from Applied Biosystems (Foster City, CA),
antibodies for the proteinase 3 (PR-3) ELISA assay were
from US Biological (Swampscott, MA), blocking buffer
(SuperBlock™ in Tris buffer) for PR-3 ELISA assay was
from Pierce Biotechnology (Rockford, IL), and TMB
(3,3′,5,5′-Tetramethylbenzidine) substrate for PR-3 ELISA
assay was from KPL (Gaithersburg, Maryland). Unless
stated, all other chemicals and reagents were purchased
from the Sigma Chemical (St. Louis).
BALF Samples The BALF samples were part of the
University of Minnesota Lung Transplant Database and
O’Brien Biobank. A total of 431 samples were collected
from 1993–1996 as a part of routine surveillance of
transplant recipients. After the mucus was filtered and the
cells were removed by centrifugation, the supernatant was
aliquoted and stored at −80°C until use. The studies were
approved by the internal review board of the University of
Minnesota. Protein analysis of the samples was exempt
under federal guidelines 45 CFR part 46.101(b).
All patients who either had been diagnosed with BOS or
who developed BOS grade 2 or higher within 100 months
after acquiring the BALF samples were included in this
study. A similar number of samples from patients who did
not develop BOS within 100 months of the sample were
also included. A total of 58 individuals and 124 BALF
samples were used in this study and were classified in three
categories: (1) samples obtained after diagnosis (BOS
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samples, 17 from 7 different patients), (2) samples taken 1 to
15 months before diagnosis of BOS (preBOS1–15, 32 samples
from 15 different patients), and (3) samples taken 16 to
76 months before the diagnosis of BOS (preBOS16–76, 27
samples from 18 individuals). Lung transplant recipients
who did not develop BOS within 100 months of sample
acquisition were referred to as controls (48 samples from 28
individuals). Table 1 shows the characteristics and clinical
information for the patients in the study.
Preparation of BALF Samples The primary objective of
this study was to identify biomarkers capable of identifying
all preBOS samples from controls. Therefore, we were
particularly interested in determining if the preBOS
samples that did not have elevated biomarkers previously
described (Clara cell protein/lysozyme ratio in MALDI-
TOF) contained other biomarkers of disease. Consequently,
the study focused on preBOS1–15 samples along with
controls and BOS for comparison. The general workflow
of the iTRAQ analysis is shown in Fig. 1. iTRAQ analysis
required at least 25 μg of protein after removal of abundant
proteins. Pooled samples provided sufficient volume and
protein concentration. Pool one was from controls (n=16),
pool 2 was from BOS samples (n=3), pool 3 was from
preBOS1–15 samples that were correctly identified as
preBOS by the Clara cell protein/lysozyme ratio in
Fig. 1 Sample flow and analysis by iTRAQ technology
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MALDI-TOF protein profile analysis [16] (true positive
samples, n=6), and pool four was from preBOS1–15
samples that were not identified by Clara cell to lysozyme
ratio analysis in the MALDI-TOF profile (false negatives,
n=6).
The pooled samples were each dialyzed against 4 L of
buffer (0.02 M NH4HCO3, pH 7.7) for 4 h at room
temperature and then overnight at 4°C against fresh buffer.
The samples were lyophilized and dissolved in 400 μL of
immunodepletion buffer A (Agilent, Wilmington, DE). The
six most abundant plasma proteins (Albumin, IgG, immu-
noglobulin A (IgA), transferrin, haptoglobin, and α–1–
antitrypsin) were removed by passage of the sample through
the multiple affinity depletion column (50×4.6 mm,
Agilent). Each sample was split into halves for sequential
application to the column. Protein concentrations were
measured by the Bradford reagent (BioRad). Samples were
examined by 15% mini-SDS-PAGE (BioRad), and an
additional depletion cycle was applied if serum albumin
was detected. The final proteins were buffer exchanged into
deionized water by ultrafiltration with Micron centrifuge
tubes (cutoff=5 K, Millipore, Bedford, MA).
Equivalent amounts of protein (26.5 ug) from each of the
four samples were subjected to trypsin digestion and iTRAQ
labeling as outlined in the manufacturer’s protocol. Briefly,
disulfides were reduced, alkylated, and samples were
trypsin-digested. Each sample was labeled with one of the
four isobaric iTRAQ reagents with reporter masses of 114,
115, 116, and 117, respectively. The samples were pooled,
and the resulting mixture speed vacuumed to dryness,
dissolved in deionized water, and purified by adsorption
and elution from a Sep-Pak C18 cartridge using standard
methods (Waters Corporation, Milford, MA). The recovered
peptide mixture was speed-vacuumed to dryness and
dissolved in 350 μl of strong cation exchange (SCX) loading
buffer [20% (v/v) acetonitrile, 5 mM KH2PO4, pH 3.2] for
subsequent fractionation.
The first dimension of separation used a SCX poly-
sulfoethyl A column (150×1.0 mm, 5 μm, 300 Å, The Nest
Group, Southborough, MA) mounted on a Magic 2002
HPLC system (Michrom Bioresources, Auburn, CA). The
iTRAQ-labeled mixture was applied to the column at a flow
rate of 100 μl/ml. Peptides were eluted with a linear
gradient of 0 to 20% elution buffer [20% (v/v) acetonitrile,
5 mM KH2PO4, 500 mM KCl, pH 3.2] over 40 min
followed by a linear 20–100% gradient over 20 min. The
elution buffer was maintained at 100% for 10 min and then
returned to the loading buffer for 5 min. Fractions were
collected at 2.5-min intervals. Peptide fractions were dried
by speed vacuum, and fractions 10 through 28 were
dissolved in 30 μl of reverse phase loading buffer [98:2,
H2O/ACN, 0.1% triflouroacetic acid (TFA)]. Each fraction
was then desalted with an LCP C18 nano-precolumn
(5×0.3 mm); they were eluted at 350 nl/min using an
LCP ultimate LC system (Dionex Company, Sunnyvale,
CA) and further separated on a reverse-phase C18 column
(13 cm×5 μm, 200 Å pore size, Michrom BioResources,
Auburn, CA), which was coupled online to a Quadrupole–
TOF mass spectrometer (QSTAR Pulsar I, Applied Bio-
systems, Foster City, CA) equipped with Protana’s nano-
electrospray source. Peptides were eluted with three stages
of linear gradient consisting of 0–30% solvent B (5:95,
H2O/ACN, 0.1% formic acid) over 0–35 min, 30–45%
solvent B from 35–45 min, and 45–50% solvent B from 45
to 50 min. Solvent A was 5% ACN in 0.1% formic acid.
The eluted peptides were subjected to in-line mass
spectrometry analysis. The product ion spectra were collected
in an IDA mode (information-dependent acquisition mode),
which included continuous cycles of a 1.5-s full scan (TOF
MS from 400–1,100 m/z) followed by product ion scans of
the three most intense ions (50–2000 m/z, 3 s each). During
the ion collection process, the instrument’s rolling collision
energy feature was used to determine collision energy based
on precursor m/z value and charge state. The electro-spray
voltage was 2,250 V, the TOF region acceleration voltage
was 4 kV, and the injection pulse repetition rate was 6.0 kHz.
The machine was calibrated using the [M+3H]3+ and
[M+2H]2+ monoisotopic peaks of human renin substrate
tetradecapeptide (m/z=586.9830 and 879.9705, Sigma-
Aldrich, St. Louis, MO).
Data Handling and Analysis Peptide identification and
relative quantification of peptides were performed using
ProQuant software (Applied Biosystems, version 1.0).
Fragment ion spectra were searched against the Celera
human database (human-KBMS3.0.20040121 generated
fall, 2004) with the Interrogator™ algorithm and a 0.35-
Da mass tolerance for both parent (MS) and fragment ions
(MS/MS). ProGroup viewer (Applied Biosystems, version
1.0.6) was used to generate compiled protein identification
and quantification results from the ProQuant database for
peptides with a ProScore of greater than 1.3 or 95%
confidence of peptide identification. This approach assumes
that peptides represent proteins in the fluid and are referred
to as such. It is recognized that this interpretation assumed
that only intact proteins were present in BALF. It also does
not consider post-translational protein modifications. While
proteins identified by more than one peptide and with a
software-generated error factor of less than 2.0 were
considered optimum (manufacturer’s description), proteins
identified by a single peptide were used for subsequent
validation by ELISA assay.
ELISA Assays ELISA kits for immunoglobulin M (IgM),
lysozyme, proMMP-9, and active MMP-9 were purchased
from Bethyl Laboratories (Montgomery, TX), ALPCO
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Diagnostics (Salem, NH), EMD Biosciences (San Diego,
CA), and R&D systems (Minneapolis, MN), respectively.
These ELISA assays were conducted following the manu-
facturers’ protocol, and data were analyzed with four-
parameter nonlinear regression using Prism (GraphPad
Software, version 4.0b).
The ELISA assay of proteinase 3 was constructed in-
house following the supplier’s protocol for assay set-up.
Highly purified human PR-3 antibody from the supplier
was reconstituted in 2 ml distilled water and diluted 100
times in coating buffer (50 mM Tris buffer, pH 8.0).
Ninety-six well ELISA plates (MediSorp™ 96 well ELISA
plate, Nunc, Rochester, NY) were coated by adding 100 μl
of diluted human PR-3 antibody and incubation for 1 h.
After the plate was washed three times with washing buffer
(50 mM Tris buffer, pH 8), blocking buffer (25%
superblock buffer in 0.15 mM saline, 200 μl) was added
to each well, and the plate was incubated for 1 h at room
temperature. Following another wash step, PR-3 serial
standards (US Biological, Swampscott, MA, 0 to 500 ng/
ml) and diluted BALF samples in blocking buffer (100 μl)
were transferred to the assigned wells, and the plate was
incubated for 1 h at room temperature. After another wash
step, 100 μl of mouse anti-human proteinase 3 antibody
(0.4 μg/ml) were added to each well followed by 1-
h incubation and another wash step. Horseradish peroxidase
(HRP)-conjugated rabbit anti-mouse IgG (100 μl, 0.1 μg/
ml) was transferred to each well and incubated for 1 h.
After a thorough washing, 100 μl of TMB (3,3′,5,5′-
tetramethylbenzidine) substrate was added, and the reaction
was stopped after a 20-min incubation in the dark by
addition of 100 μl of stopping solution (2 M H2SO4). The
absorbance was measured at 450 nm using an Elx8000
plate reader (BioTek Instruments, Winooski, VT). All of the
antibodies were purchased from US Biological (Swamp-
scott, MA). All steps were conducted at room temperature.
All ELISA data represent average and standard deviation
of triplicate measurements. The protein concentrations
measured using ELISA assays were analyzed by Prism
software nonlinear regression analysis. The concentrations
of the target proteins were normalized to total protein, to
lysozyme concentration in each sample, or to volume of
sample assayed. Statistical analyses were conducted in
either Microsoft Excel or R program.
Results
Relative Protein Quantification of BALF Proteins by
iTRAQ Pooled samples consisted of controls (samples from
subjects who did not develop BOS within 100 months of
the sample), disease (samples from subjects post-diagnosis
of BOS), and pre-disease. The latter group included two
types: samples from individuals that were collected 1–
15 months before BOS who were accurately predicted by
existing biomarkers [true (+), Table 2] and samples from
individuals that were collected 1–15 months before BOS
who were not detected by the existing biomarkers [false
(−), Table 2]. The iTRAQ analysis resulted in confident
(>95%) identification of peptides from 265 proteins. Of
these, 117 proteins were identified by more than two
peptides and quantified with an error factor less than 2.0 as
assessed by the software program. These criteria are
accepted for determination of a protein ratio on the basis
of mass spectrometry data alone.
The current study used mass spectrometry for discovery
of candidate biomarkers but used other methods for
validation. For example, in the absence of corroborating
results, protein ratios determined by a single peptide are not
considered accurate. However, follow-up analysis by a
separate method such as ELISA allows the use of proteins
identified by only one peptide, as the second method
effectively detects false detection in the iTRAQ experiment.
For this reason, we utilized all 265 potential proteins to
identify targets for subsequent analysis.
The criterion used to identify proteins for additional
study was greater than a threefold change in all categories
of disease and pre-disease relative to controls. Table 2
shows a list of these proteins along with their molecular
function, biological process, and relative protein ratios.
These results suggested that diagnosis of disease could be
accomplished by analysis of a very large portion of the
proteins identified. However, the target group was pre-BOS
that gave false negative results for biomarkers found in
previous studies.
Proteins that met the primary criterion included cell
surface and cell matrix proteins, cytoskeleton proteins,
surfactants, and antimicrobial peptides. These were not
immediately targeted because they were considered to be
evidence of cell destruction, a process known to occur in
BOS, or were identified as house-keeping proteins or
correlated with other antimicrobial peptides, such as human
neutrophil peptide (HNP), that we documented in a
previous study. The proteins of greatest interest were those
that might be responsible for cellular destruction such as
proteinase 3 and metalloproteinase 9. IgM gave a large
change that may also represent a unique immune response.
Therefore, these proteins were targeted for further study.
An unidentified protein (accession number dbj|BAC86931.1)
was also up regulated in disease. Validity was not highly
certain, as it was identified by a single peptide. Furthermore,
functional information as well as antibodies for this protein
were lacking. Overall, additional information would be
required to warrant expenditure of the effort required for
analysis by ELISA or other quantitative method.
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Validation of Biomarkers by ELISA The 124 individual
BALF samples were subjected to ELISA assay for
quantification of the potential biomarkers. The medians
and 25–75% quartile results for IgM, lysozyme, PR-3, the
latent form MMP-9 (proMMP-9), and the active MMP-9
(aMMP-9) from the individual lavage samples are given in
Table 3.
Controls (those who did not develop chronic rejection)
showed very similar levels of PR-3 (Fig. 2a). However,
levels started to increase a few months before the diagnosis
of BOS, and a high concentration was maintained for at
least 15 months after diagnosis. As a result, PR-3 in samples
with chronic rejection (median=1,337 ng/mg, inter-quartile
range (IQR), from 735 to 4,106 ng/mg) was significantly
higher than that of controls (median=152 ng/mg, IQR of 65
to 246, p<0.0001; Table 3).
MMP-9 exists in two forms: latent (proMMP-9, 92 kD)
and active (aMMP-9, 85 kD). The active form arises from
cleavage of the amino-terminal domain (propeptide do-
main) from the latent form. Latent MMP-9 was dramati-
cally higher in samples with chronic rejection (median=
837 ng/mg, IQR of 279 to 3,058 ng/mg) than in controls
(median=12.7 ng/mg, IQR of 4.68 to 64.7, p<0.0001,
Table 3). In addition, a significant increase of proMMP-9
was found preBOS1–15 (Fig. 2b). Greater than 15 months
before BOS, proMMP-9 was present at approximately the
same level as controls. Surprisingly, aMMP-9 showed a
relatively stable level across different BOS stages (Table 3).
For IgM, iTRAQ analysis indicated more than sevenfold
difference between disease and control samples (p=0.002).
This difference, however, arose largely from three samples
in the disease group that had extremely high readings.
Significance was lost if the three extreme samples were
excluded from statistical comparisons (not shown). In
addition, no significant difference was found for IgM in
control vs any preBOS group (Table 3).
Different Methods of Normalization BALF is a heteroge-
neous fluid that is expected to vary in content depending on
the region of the lung extracted, mixing of the fluid during
the procedure, and other technical factors. It can also vary
with the actual protein content of the lung fluid. This raises
the question of the appropriate method of biomarker
normalization. Concentration can be expressed as a func-
tion of total protein in the extract, on the basis of volume of
fluid or by comparison to an internal protein marker.
Lysozyme remained relatively constant in BALF fluid as
judged by mass spectrometry methods (Fig. 3a) conducted
with a constant amount of protein. ELISA analysis also
showed consistency in disease vs controls when lysozyme
was expressed as a function of protein concentration
(Fig. 3a). This resulted in a lack of diagnostic power for
lysozyme (Fig. 3a) but provided a stable internal standard
for comparison to other biomarkers.
Figure 3b showed that disease correlated with higher
protein concentrations in BALF, making total protein a
Table 2 Partial protein list from iTRAQ










1 gb|AAM97934.1 Matrix metalloproteinase 9 Protease 9 14.5 3.2 10.4
2 gb|AAB59493.1 Proteinase 3 Protease 1 124.6 59.9 26.0
3 rf|NP_000886.1 Leukotriene A4 hydrolase Hydrolase 1 6.8 3.0 3.2
4 trm|Q12760 Glutathione S-transferase Transferase 1 0.1 0.3 0.1
5 trm|Q8N8T4 Hypothetical protein FLJ38902 Transcription factor 1 0.2 0.3 0.3
6 trm|Q8WWQ5 Mucin 5 Extracellular matrix 21 6.2 3.0 3.4
7 rf|XP_039877.6 Mucin 5B precursor Extracellular matrix 20 4.9 4.0 3.0
8 gb|AAA88083.1 Hexabrachion Extracellular matrix 1 18.0 4.1 3.6
9 gb|AAF35390.1 Voltage-gated sodium channel alpha subunit Ion channel 1 6.5 3.3 7.9
10 pir|A61231 Myosin heavy chain nonmuscle form A Cytoskeletal protein 7 3.9 3.9 4.4
11 spt|Q9UIF3 Tektin 2 Cytoskeletal protein 1 5.1 10.1 4.0
12 spt|P05107 Integrin beta-2 precursor Receptor 1 9.0 5.0 7.0
13 trm|Q9BTR2 Mesothelin Cell adhesion 4 0.1 0.3 0.2
14 pdb|1PW9_A Human lung surfactant, A chain A Defense/immunity 4 0.2 0.2 0.1
15 pdb|1MHL_C Myeloperoxidase isoform C Oxidoreductase 24 4.7 3.0 4.5
16 rf|NP_004659.1 Maltase-glucoamylase Hydrolase 2 6.0 3.9 6.2
17 dbj|BAC86931.1 Unnamed protein product 1 38.4 24.0 26.6
18 prf|1617124A Cationic antimicrobial protein CAP37 Protease 5 16.1 5.5 10.4
19 rf|NP_004336.1 Cathelicidin antimicrobial peptide Defense/immunity 2 6.0 8.8 4.7
20 pdb|1ADQ_L Igm rheumatoid factor Fab, L chain Defense/immunity 2 7.8 13.6 14.7
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biomarker with modest diagnostic power (Fig. 3b). As a
result, analysis of biomarkers on the basis of total protein, on
the basis of biomarker ratio to lysozyme concentration or on
the basis of BALF volume resulted in different outcomes.
ROC curve analysis for biomarkers normalized to
volume (/ml), total protein (/mg total protein), or to
lysozyme level (/mg lysozyme) are compared in Fig. 4.
As expected from the results in Fig. 3, biomarker
concentration normalized to lysozyme, or volume showed
better outcomes than biomarker concentrations normalized
to total protein.
Fig. 2 Biomarker changes as a function of time to diagnosis of BOS.
a Proteinase 3. Diagnosis of BOS was assigned time zero. Controls
are those without BOS for at least 100 months (shown at −100) from
the time of sample collection. One sample at 67 ug/mg at −15 months
to BOS is not shown. b Latent form of MMP-9 (ProMMP-9). Four
samples with very high readings are presented in a condensed scale. In
both panels, the average and standard deviation of three assays is
shown
Table 3 Summary of ELISA results indicated as median (25%, 75% quartile)








Control 48 0.96 (0.37, 1.85) 6.32 (3.55,
12.1)
152 (65, 246) 12.7 (4.68, 64.7) 11.1 (3.45,
33.2)
0.53 (0.18, 1.21)
PreBOS16–76 27 0.75 (0.35, 1.54) 3.47 (1.74,
8.73)
36 (15, 243) 19.6 (2.31, 58.2) 19.3 (8.83,
38.0)
0.97 (0.17, 1.71)
PreBOS1–15 32 1.31 (0.41, 3.44) 4.88 (2.68,
8.98)
247 (33, 1,543) 112 (13.2, 508)*** 9.33 (3.09,
26.8)
1.83 (0.53, 2.99)**
BOS 17 2.35 (0.59, 5.18)** 6.47 (3.20,
11.2)
1,337 (735, 4,106)* 837 (279, 3058)* 20.2 (9.09,
23.8)
2.25 (0.79, 3.16)**




Fig. 3 Distribution and ROC curves for lysozyme and total protein. a
Lysozyme. The concentration distribution (a1) and ROC curve
analysis (a2) is shown for lysozyme when normalized to the total
protein. b Protein concentration distribution (b1) and ROC curve (b2)
for protein concentration in BALF. In both panels, the distributions of
biomarkers are illustrated in a box plot (a1/b1). The bold horizontal
line in the middle of the box indicates the median value. The upper
and lower hinges of the box indicate the 25th and 75th percentile
values. The experimental points outside of the box indicate the
extreme values in that group, and the dashed lines connected to the
box indicate the minimum or the maximum value in the dataset.
The curves were constructed from data for BOS and control samples
Clin Proteom (2007) 3:3–12 9
PR-3 gave a maximum specificity of 92% and sensitivity
of 76% (Fig. 4), whereas ProMMP-9 gave a maximum
specificity of 92% and sensitivity of 82% (Fig. 4).
Reanalysis of HNP levels from published results [17] also
showed improved outcome when normalized to volume or
lysozyme concentration (Fig. 4). No significant discrimina-
tion power was found for IgM (Fig. 4) or aMMP-9 (data not
shown).
Discussion
Lung transplantation is an effective strategy for the
treatment of end-stage lung disease. Unfortunately, chronic
rejection remains a major obstacle to long-term survival.
This study utilized proteomic approaches, specifically
iTRAQ labeling coupled with mass spectrometry, to
discover additional disease biomarkers that might provide
improved diagnosis and prediction of transplant rejection,
and to improve our understanding of disease mechanism.
The advantage of iTRAQ labeling is that, in theory, all
proteins can be labeled. However, in samples with abundant
proteins, such as albumin, these proteins can be dispropor-
tionately labeled, and therefore, low abundance proteins are
missed. To detect low abundance proteins, samples were
subjected to affinity removal of six abundant proteins by a
multiple affinity column [18]. This removed a significant
proportion of the protein within the BALF. Most individual
BALF samples had inadequate protein for individual
iTRAQ analysis. The use of pooled samples provided
adequate protein. However, this necessitated the validation
of discovery by another approach to ensure that results were
representative of all the samples and were not biased by
outlier values. Peptides from a total of 265 proteins were
identified with high confidence. One hundred seventeen
proteins were identified by two or more peptides and with
satisfactory error factors. Of the 117 proteins, two thirds
differed by more than twofold between controls and
disease. Some of the proteins have been associated with
other severe diseases of the lung, including calgranulin B in
pneumonia [19], glutathione S-transferase in lung cancer
[20], and PR-3 in acute respiratory distress syndrome
(ARDS) [21]. We chose a subset of proteins (MMP9, PR-
3, and IgM) that were both highly up-regulated and that
may be linked to disease mechanism for more detailed
analysis.
A peptide of PR-3, a neutral serine proteinase, had the
largest fold increase in samples taken at the time of BOS
and preBOS. Although PR-3 was represented by a single
peptide, it was chosen for further ELISA. PR-3 is capable
of degrading such extra-cellular proteins as elastin, fibro-
nectin, and type IV collagen [22–24]. PR-3 is associated
with several other lung diseases including Wegener’s
granulomatosis, cystic fibrosis, and acute respiratory dis-
tress syndrome (ARDS) [21, 25, 26]. With regards to
mechanism of disease, the highly elevated PR-3 level
suggested that proteinase activity may disrupt normal lung
tissue structure and play an important role in the develop-
ment of proliferation and fibrosis of small airways.
Furthermore, PR-3 can activate matrix metalloproteinase-2
(MMP-2) and matrix metalloproteinase-9 (MMP-9) [27],
another biomarker found in this study.
The iTRAQ data reported over a tenfold increase in the
92-kD proMMP-9 form in disease. We performed ELISA
for both the pro- and the active forms. We found a
significant increase in the both the pro- and the active
forms in disease; however, only the pro-form was elevated
before the onset of disease. MMP-9 is a member of the
zinc- and calcium-dependent proteinase family that is
involved in the degradation and remodeling of the extra-
Fig. 4 ROC curve analysis of HNP, PR-3, IgM, and proMMP-9
normalized to various standards. The ROC curve analysis was
performed for biomarker concentrations normalized to volume of
BALF assayed (analysis marked 1), total protein (analysis marked 2),
and lysozyme content (analysis marked 3) of BALF. a Human
neutrophil defensins (HNP). Data were from a previous study 17. b
Proteinase 3 (PR-3). c IgM. d Latent form of matrix metalloprotei-
nase-9 (proMMP-9). Area under the curve (AUC) is given. An area of
1.0 represents perfect sensitivity and specificity, whereas an area of
0.5 represents random assignment
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cellular matrix. MMP-9 is secreted as a 92-kD pro-form
that is cleaved into an 83-kD active form. Metalloprotei-
nases have been associated with many physiological and
pathological processes such as cancer, arthritis, wound
healing, bone remodeling, atherosclerosis, chronic obstruc-
tive pulmonary disease (COPD), lung fibrosis, and lung
cancer [27–31]. Moreover, MMP-9 knockout mice are
resistant to autoimmune encephalomyelitis and other types
of induced inflammation pathologies (e.g., tail pathology)
[32]. It has been suggested that MMP-9 may play an
important role in the regulation of the immune system in
addition to its modulation of the extra-cellular matrix. This
function may distinguish MMP-9 from other members of
the MMP family [33].
When normalized to total protein, ELISA analysis of
lysozyme showed no correlation with progression to BOS.
This confirmed a previous study where Clara cell protein in
BALF was expressed relative to lysozyme by a mass
spectrometry method [16]. The stability of lysozyme
allowed it to be used as an internal standard for other
biomarkers. Normalizing to lysozyme resulted in a small
improvement in biomarker sensitivity and specificity. Total
protein was also a biomarker for disease. This was not
surprising because increased protein might arise from
advancing lung injury that resulted in greater secretion of
proteins into the airway. Because BALF protein was
elevated in disease, biomarkers normalized to total protein
would show lowered sensitivity. It is unlikely that total
protein will be a specific biomarker for BOS, as it is likely
elevated in many disease states, such as infection, that could
affect the allograft. Prospective validation with correction for
concomitant diseases will be needed to validate this
suggestion. Consequently, normalization of the biomarker
concentration to BALF volume resulted in somewhat better
outcomes for both the diagnosis and prediction of disease.
Whereas the optimum basis for biomarker normalization
may be BALF volume, this conclusion should be approached
with caution, as protein concentration of BALF may also
vary with technical methods.
Overall, chronic lung allograft rejection is a complex,
progressive disease that is likely to involve different events
and pathways, each of which will be characterized by the
up or down regulation of different proteins. A panel of
biomarkers may be needed to characterize all pathways and
stages of disease. Identification of PR-3 and MMP-9
increased the number of biomarkers of lung transplant
rejection and suggested additional factors that may contrib-
ute to lung deterioration in chronic rejection and may even
provide ideas for therapeutic targets for chronic rejection.
This study also provided an illustration of biomarker
discovery in pooled samples with subsequent validation
by analysis of individual samples with orthogonal technol-
ogy. The findings illustrated the limitation of pooled sample
analysis where up-regulation of IgM was not representative
of chronic rejection but was caused by a few extreme
outliers. Finally, validation of these biomarkers, alone and
in combination, is being conducted as part of a large
prospective study that is in progress.
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